Although there are no established screening or intervention strategies for male carriers of BRCA1/2 mutations, few clinical management recommendations include education, clinical breast examination, and prostate cancer screening.39 The present findings may inform the development of clinical recommendations on the basis of polygenic risk stratification of male mutation carriers to personalize management recommendations. The gene discussed is BRCA1; the disease is prostate cancer.